{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:08:30Z","timestamp":1795003710445,"version":"4.9.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The antimalaria 4-aminoquinoline drugs chloroquine and HCQ are used in the treatment of a wide range of CTDs. Data to inform on the safety of their use in pregnancy are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a Danish nationwide cohort study from 1996 through 2016, we identified 4-aminoquinoline\u2013exposed pregnancies from a cohort of 1\u202f240\u202f875 pregnancies to investigate the associated risks of major birth defects, preterm birth, and small size for gestational age (SGA). Distinct study cohorts of propensity-score\u2013matched 4-aminoquinoline-exposed and unexposed pregnancies (in a 1:1 ratio) were established for each outcome analysis. The association with the outcomes was assessed by prevalence odds ratios (ORs) estimated through logistic regression. The associated risks for chloroquine and HCQ were individually assessed through additional analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1487 pregnancies exposed to 4-aminoquinolines (1184 chloroquine- and 303 HCQ-exposed) were identified. Among the 983 pregnancies exposed to 4-aminoquinolines in the first trimester, 34 infants (3.5%) were diagnosed with major birth defects as compared with 36 (3.7%) among the matched unexposed pregnancies (prevalence OR, 0.94; 95% CI: 0.59, 1.52). Exposure to 4-aminoquinolines in pregnancy was neither associated with an increased risk of preterm birth (prevalence OR, 0.97; 95% CI: 0.73, 1.28) or SGA (prevalence OR, 1.18; 95% CI: 0.93, 1.50), compared with unexposed pregnancies. No significant associations between exposure to chloroquine or HCQ individually and risk of the outcomes were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among pregnancies exposed to 4-aminoquinolines (chloroquine and HCQ), no increased risk of major birth defects, preterm birth, or SGA was identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa592","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:09:46Z","timestamp":1597950586000},"page":"2317-2326","source":"Crossref","is-referenced-by-count":51,"title":["Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-6303","authenticated-orcid":false,"given":"Niklas Worm","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Epidemiology Research, Statens Serum Institut"},{"name":"Department of Clinical Pharmacology, Bispebjerg and Frederiksberg, Copenhagen University Hospital"},{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Tr\u00e6rup","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Bispebjerg and Frederiksberg, Copenhagen University Hospital"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"2021051418595110900_keaa592-B1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/36.7.799","article-title":"Antimalarial drugs in the treatment of rheumatological diseases","volume":"36","author":"Rynes","year":"1997","journal-title":"Rheumatology"},{"key":"2021051418595110900_keaa592-B2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/14740338.2018.1535593","article-title":"Antimalarial drugs for treating and preventing malaria in pregnant and lactating women","volume":"17","author":"Saito","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2021051418595110900_keaa592-B3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"2021051418595110900_keaa592-B4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus\u2013guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021051418595110900_keaa592-B5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/14740338.2011.566555","article-title":"Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy","volume":"10","author":"Abarientos","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"2021051418595110900_keaa592-B6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.rdc.2007.01.002","article-title":"Lupus activity in pregnancy","volume":"33","author":"Clowse","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"2021051418595110900_keaa592-B7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/bmj.290.6480.1466","article-title":"Safety of chloroquine in chemosuppression of malaria during pregnancy","volume":"290","author":"Wolfe","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2021051418595110900_keaa592-B8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.reprotox.2013.04.005","article-title":"Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study","volume":"39","author":"Diav-Citrin","year":"2013","journal-title":"Reprod Toxicol"},{"key":"2021051418595110900_keaa592-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488606775252584","article-title":"Antimalarial drugs in pregnancy: a review","volume":"1","author":"Nosten","year":"2006","journal-title":"Curr Drug Saf"},{"key":"2021051418595110900_keaa592-B10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.12872","article-title":"Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis","volume":"81","author":"Kaplan","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2021051418595110900_keaa592-B11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2007-999371","article-title":"Pregnancy outcome following first trimester exposure to chloroquine","volume":"8","author":"Levy","year":"1991","journal-title":"Am J Perinatol"},{"key":"2021051418595110900_keaa592-B12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.55.7.486","article-title":"Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases","volume":"55","author":"Buchanan","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"2021051418595110900_keaa592-B13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0002-9343(88)90359-2","article-title":"Antimalarial drugs and pregnancy","volume":"85","author":"Parke","year":"1988","journal-title":"Am J Med"},{"key":"2021051418595110900_keaa592-B14","first-page":"1715","article-title":"Hydroxychloroquine in pregnant patients with systemic lupus erythematosus","volume":"23","author":"Parke","year":"1996","journal-title":"J Rheumatol"},{"key":"2021051418595110900_keaa592-B15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Brief report: risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021051418595110900_keaa592-B16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/art.10150","article-title":"Evidence of transplacental passage of hydroxychloroquine in humans","volume":"46","author":"Costedoat-Chalumeau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021051418595110900_keaa592-B17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00007691-198802000-00004","article-title":"Placental and milk transfer of chloroquine in humans","volume":"10","author":"Akintonwa","year":"1988","journal-title":"Ther Drug Monit"},{"key":"2021051418595110900_keaa592-B18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2125.2008.03111.x","article-title":"Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers","volume":"65","author":"Law","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2021051418595110900_keaa592-B19","volume-title":"Aralen\u00ae (chloroquine phosphate package insert)","year":"2018"},{"key":"2021051418595110900_keaa592-B20","first-page":"320","article-title":"The Danish Medical Birth Registry","volume":"45","author":"Knudsen","year":"1998","journal-title":"Dan Med Bull"},{"key":"2021051418595110900_keaa592-B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021051418595110900_keaa592-B22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021051418595110900_keaa592-B23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021051418595110900_keaa592-B24"},{"key":"2021051418595110900_keaa592-B25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2021051418595110900_keaa592-B26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"2021051418595110900_keaa592-B27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2021051418595110900_keaa592-B28","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity\u2013score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2021051418595110900_keaa592-B29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/pan\/mpl013","article-title":"Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference","volume":"15","author":"Ho","year":"2007","journal-title":"Polit Anal"},{"key":"2021051418595110900_keaa592-B30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1473-3099(07)70025-7","article-title":"Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance","volume":"7","author":"Ward","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"2021051418595110900_keaa592-B31"},{"key":"2021051418595110900_keaa592-B32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-3156.2006.01778.x","article-title":"Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Villegas","year":"2007","journal-title":"Trop Med Int Health"},{"key":"2021051418595110900_keaa592-B33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200767010-00006","article-title":"Ocular adverse effects associated with systemic medications: recognition and management","volume":"67","author":"Santaella","year":"2007","journal-title":"Drugs"},{"key":"2021051418595110900_keaa592-B34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/acr.23808","article-title":"Risk of ocular anomalies in children exposed in utero to antimalarials: a systematic literature review","volume":"71","author":"Gaffar","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2021051418595110900_keaa592-B35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.jp.7211208","article-title":"Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation","volume":"25","author":"Motta","year":"2005","journal-title":"J Perinatol"},{"key":"2021051418595110900_keaa592-B36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(01)06004-4","article-title":"Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases","volume":"358","author":"Klinger","year":"2001","journal-title":"Lancet"},{"key":"2021051418595110900_keaa592-B37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1191\/0961203304lu528oa","article-title":"Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry","volume":"13","author":"Borba","year":"2004","journal-title":"Lupus"},{"key":"2021051418595110900_keaa592-B38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2317\/37935860\/keaa592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2317\/37935860\/keaa592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T19:00:43Z","timestamp":1621018843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/5\/2317\/6000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,11,24]]},"published-print":{"date-parts":[[2021,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa592","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,11,24]]}}}